GlassScriptPhysician profile
Pinal Chokshi
NPI 1497148118
$2,985.20
in general payments reported to CMS, 2019-2025
13 companies · $989 in 2025
The $989 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.34 · 2020: $99.00 · 2021: $77.99 · 2023: $170 · 2024: $1,622 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,698 · Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,697.50 |
| Food and Beverage | $1,083.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,707.93 | 2024-2025 | Datroway, Enhertu |
| Inari Medical, INC. | $319.29 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Tempus Ai, INC | $208.97 | 2024-2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $140.66 | 2024-2025 | Enhertu |
| Stryker Corporation | $139.29 | 2025 | Clottriever Bold Catheter, Venacore Thrombectomy Catheter |
| Merck Sharp & Dohme LLC | $115.94 | 2024-2025 | Keytruda, Keytruda Qlex |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2020 | |
| Stemline Therapeutics INC. | $81.39 | 2023-2025 | Orserdu |
| Incyte Corporation | $77.99 | 2021 | |
| Ge Healthcare | $35.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.35 | 2025 | |
| Amgen INC. | $27.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinal Chokshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.